Suven Life Sciences Limited has informed the Exchange regarding a press release dated December 07, 2015, titled “Suven Initiates Phase 2A trial of SUVN-502 in USA in Alzheimer s Disease”…….
| Subscribe To Our Free Newsletter |
The Most Valuable Commodity Is Information!
